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Coralia N. Mihu,1 Jenifer Schaub,1 Sandra Kesh,1 Ann Jakubowski,2 Kent Sepkowitz,1
Eric G. Pamer,1 Genovefa A. Papanicolaou1We report on the incidence, risk factors, and outcome of late Staphylococcus aureus bacteremia (SAB) in a co-
hort of 709 adult and pediatric patients at Memorial Sloan-Kettering Cancer Center between September
1999 and December 2006. The SAB cases were identified by prospective surveillance and examination of
a computerized database. Late SAB was defined as SAB occurring . 50 days post-hematopoietic stem
cell transplantation (HSCT). A nested case-controlled study was conducted to identify predictors of late
SAB. The incidence of late SAB was 6/100,000 patient-days. The median time from stem cell infusion to in-
cident blood culture was 137 days (range, 55 to 581 days). Eighty-four percent of the cases were community
acquired; 40% involved a focal infection. Bacteremia was persistent (.3 days) despite removal of endovas-
cular access in. 50% of cases. Risk factors for late SAB were acute graft-versus-host disease (aGVHD) flare,
acute or chronic skin GVHD (cGVHD), corticosteroid use, liver dysfunction, and prolonged hospital length
of stay (LOS) post-HSCT. In multivariate models, skin GVHD (P 5 .002) and LOS (P 5 .02) remained signif-
icant. The median survival post-SAB was 135 days (range, 1 to 1765 days). Late SAB occurred mainly in the
setting of GVHD or corticosteroid therapy. Clinical manifestations were highly variable. Multiple comorbid-
ities, indicated by organ dysfunction and hospitalization, likely contributed to persistence and increased mor-
bidity and mortality. We recommend a high index of suspicion and empiric antistaphylococcal treatment
pending culture results in high-risk patients undergoing HSCT.
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Bacteremia is the most common infection after
allogeneic hematopoietic stem cell transplantation
(HSCT), with a reported incidence of up to 40% [1].
Staphylococcus aureus bacteremia (SAB) has been associ-
ated with considerable morbidity and mortality in var-
ious clinical settings [2,3]. Despite a predominance ofDepartment of Medicine, 1Infectious Disease; and 2Bone
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6/j.bbmt.2008.09.005gram-positive organisms, S aureus is a rather rare cause
of bacteremia in HSCT, with a reported incidence of
1% to 3% [4]. Importantly, the reported mortality
attributed to S aureus is quite low compared with rates
in non-HSCT patients [5]. The present study was con-
ducted to investigate the incidence, risk factors, and
outcome of postengraftment SAB.METHODS
Study Patients
The study was approved by the Memorial Sloan
Kettering Cancer Center (MSKCC) Institutional
Review Board. The cohort comprised 709 consecutive
adult and pediatric patients who underwent allogeneic
HSCT at MSKCC between September 1, 1999 and
December 31, 2006. Patients were censored at relapse
or second HSCT. Cases of late SAB were identified by
examining a computerized microbiology database and1429
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data were extracted from medical records.Definitions
Late SAB was defined as at least 1 set of blood
cultures positive for S aureus with clinical signs of in-
fection occurring . 50 days after HSCT. All cultures
were processed by the MSKCCClinical Microbiology
Laboratory. Follow-up blood cultures were obtained
routinely in patients with positive cultures. SAB was
considered nosocomial if the incident blood culture
was drawn . 72 hours after admission. SAB was con-
sidered sustained if blood cultures were positive for
$ 3 days within 1 week of the incident blood culture.
The recurrence interval was 7 days. Septic shock was
defined as a systolic blood pressure \ 90 mm Hg,
with evidence of peripheral hypoperfusion. Pneumo-
nia was defined as new infiltrates detected on chest
radiograph and a positive bronchoalveolar lavage or
endotracheal aspirate culture for S aureus. Endocardi-
tis was defined by Duke’s criteria [6]. A central venous
catheter (CVC) was considered the source of infection
if bacteremia resolved promptly after catheter removal
and if no other focus of infection was identified. Pocket
and tunnel infections associated with intravascular de-
vices were defined according to standard criteria [7].
Case fatality was defined as death occurring within 7
days of the incident blood culture.
Time to myeloid engraftment was calculated as the
number of days from stem cell infusion to an absolute
neutrophil count (ANC) $ 1000/mm3 on 2 consecu-
tive days after stem cell infusion. Secondary neutrope-
nia was defined as ANC # 1000/mm3 on $ 2
consecutive measurements after having achieved neu-
trophil recovery and within 30 days of SAB. Liver or
kidney dysfunction was defined as a $ 2 consecutive
measurements of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), or bilirubin . 3
times the upper limit of normal and creatinine . 2
times the upper limit of normal, respectively, between
day 140 post-HSCT and the date of the incident
blood culture. Values for CD41 and CD81 lympho-
cyte subsets and serum IgG levels at 6 months post-
HSCT were recorded. Graft-versus-host-disease
(GVHD) was graded by standard criteria [8]. Cortico-
steroid use was defined as $ 1 mg/kg/day of methyl-
prednisolone or equivalent for $ 14 days within
30 days before the incident blood culture. Use of
steroid-sparing immunosuppressants was recorded if
administered for $ 7 days within 30 days of the inci-
dent blood culture. Any antibiotic use for $ 7 consec-
utive days within 30 days of the incident blood culture
was recorded. Overall hospital length of stay (LOS)
was calculated as the total number of days in the
hospital between day 40 post-HSCT and the date of
the incident blood culture.Conditioning regimens containing fractionated
total body irradiation (TBI) included thiotepa and
cyclophosphamide (Cy) or thiotepa and fludarabine
(Flu). The non-TBI–containing regimens included
busulfan (Bu) and Cy or Bu and melphalan (Mel).
Recipients of unmodified HSCT received standard
GVHD prophylaxis with methotrexate (MTX) or
(CsA) cyclosporine-A. Recipients of T cell–depleted
transplants did not receive any additional GVHD pro-
phylaxis.
Standard care of HSCT recipients included
fluconazole and acyclovir starting at cytoreduction.
Patients also received Pneumocystis prophylaxis with
trimethoprim-sulfamethoxazole or pentamidine (in
case of sulfa allergy) from day 27 to day 23. No
routine antibacterial prophylaxis was given to the
patients undergoing HSCT until December 2005.
Starting on December 1, 2005, adult patients who
underwent myeloablative conditioning received vanco-
mycin prophylaxis starting at day -2 relative to stem cell
infusion through day 17 post-HSCT.Statistical Analysis
To determine risk factors for late SAB, we con-
ducted a nested case-controlled study. Three controls
for each case were then randomly selected from the
same cohort and matched to cases on duration of
follow-up, age (within 5 years), sex, and donor rela-
tionship. Each variable was initially analyzed in univar-
iate models using conditional logistic regression.
Significant variables were then combined into a single
multivariate model. The final multivariate model was
selected through best-subsets selection, using the
score statistic as the selection criterion. Results were
considered statistically significant if the P values
from the likelihood ratio test were\ .05. Survival plots
were constructed using Kaplan-Meier method. Differ-
ences in survival curves were determined using log-
rank test. All data analyses were done using SAS
version 9.1 (SAS Institute, Cary, NC).RESULTS
Incidence of Postengraftment SAB
Table 1 summarizes the characteristics of the co-
hort of 709 consecutive adult and pediatric patients
who underwent HSCT. Median follow-up was 680
days (range, 66 to 2443 days). Twenty-nine of the
709 patients (4.1%) developed SAB. Twenty-six pa-
tients (3.6%) developed late SAB, a median of 137
days (range, 52 to 581 days) after HSCT. The inci-
dence of late SAB was 6.0/100,000 patient days; 22
(84.6%) of these cases were community-acquired.
The incidence of SABwas similar in adult and pediatric
HSCT recipients (3.5% vs 3.8%; P5 not significant).
Table 1. Baseline Characteristics of Patients Undergoing
Allogeneic HSCTat MSKCC between September 1, 1999, and
December 31, 2006 (n 5 709)
Age, years, median (range) 34.4 (0-71.3)
Sex, male, n (%) 411 (57.9)
Diagnosis, n (%)
Acute lymphoblastic leukemia 120 (16.9)
Acute myeloblastic leukemia 197 (27.9)
Chronic myelogenous leukemia 38 (5.3)
Myelodysplastic syndrome 85 (11.9)
Lymphoma 127 (17.9)
Other myeloproliferative disorder 41 (5.8)
Nonmalignant condition 101 (14.2)
Donor type, n (%)
Matched sibling 317 (44.7)
Mismatched related 60 (8.5)
Matched unrelated 332 (46.8)
T cell depletion, n (%) 408 (57.5)
Conditioning, n (%)
Myeloablative
TBI- based 320 (45.1)
Non TBI; all chemotherapy 265 (37.4)
Nonmyeloablative 124 (17.5)
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Figure 1. Kaplan Meier probability of overall survival after diagnosis of
SAB. Cases had lower survival compared to controls (p50.0002).
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in our cohort was 23%, compared to 38% in blood
isolates of non-HSCT patients at MSKCC during
the same period (p5not significant).
Clinical Presentation of Late SAB
The majority of patients (80.7%) presented with
fever. Shock was noted at presentation in 42.3% of pa-
tients. Twelve patients (46.2%) had focal infections
with S aureus. The most common manifestation was
pneumonia, seen in 5 patients (19.2%). Three patients
(11.5%) presented with skinmanifestations without fe-
ver, including paronychia in 1 patient, superficial
thrombophlebitis at an old i.v. site in 1 patient, and
septic emboli in 1 patient. Four patients (15.3%) had
a pocket or tunnel infection. Three patients (11.5%)
had right-sided endocarditis.
Twenty-two of 29 (84.6%) patients had an in-
dwelling CVC at presentation. TheCVCwas removed
in 19 of these patients (86%), a median of 3 days from
the date of the incident blood culture (range, 1 to 8
days). Eleven patients (57.9%) had persistent SAB de-
spite CVC removal. Eight of 15 catheter tips sent for
culture (53.3%) were positive for S aureus.
Late SAB cases had decreased overall survival com-
pared to controls (p50.0002) (Figure 1). Four (15.4%)
patients died within 7 days (range, 1 to 7 days) of the
incident blood culture.
Risk Factors for Late SAB
We conducted a nested case-controlled study to
determine predictors for late SAB. Three controls
were selected randomly from the cohort matched to
cases by age, sex, donor type, and survival status. Table
2 presents the results of the univariate analysis. Risk
factors for late SAB included acute GVHD (aGVHD),
skin GVHD (acute or chronic), liver dysfunction, andincreased hospital LOS. CD41 and CD81 T lympho-
cyte counts, serum IgG levels, and secondary neutro-
penia did not differ between the SAB cases and
controls. When all significant variables were entered
into the multivariate models, only LOS and GVHD
involving the skin remained significant (Table 3).DISCUSSION
SAB has been associated with significant morbidity
andmortality in various clinical settings, evenwhen con-
trolled for severity of illness [9]. In neutropenic patients
with cancer, the incidence of SAB is 6% to 7%, with an
overall mortality of 23% to 40% [12]. A large study of
patients who underwent bone marrow transplantation
found an SAB incidence of 3% over a 7-year period,
with no attributable mortality [4]. At our institution,
S aureus was a rare cause of bloodstream infection
early posttransplantation (incidence \ 0.5%). The
heavy use of broad-spectrum antibiotics in the peri-
transplantation period may be a factor in this low in-
cidence of early SAB. In contrast, the incidence of
late SAB at our institution is 3.6%, at a rate 6/
100,000 HSCT-days.
Previous studies inHSCT recipients have reported
low SAB-associated mortality in HSCT. A more re-
cent study found high rates of septic shock and death
associated with SAB in patients with hematologic ma-
lignancies (although only 9 of 34 patients had under-
gone HSCT and 17 of 34 had neutropenia, including
the 6 who died of septic shock) [10]. In our cohort,
the case fatality rate was 15%, with an attributable
mortality rate of 8%. SAB was associated with
Table 2. Univariate Analysis of Risk Factors for Late SAB
Variable Cases (n 5 26) Controls (n 5 78) Odds Ratio (95% Confidence Interval) P Value
GVHD, n (%)
Acute GVHD 12 (46.2%) 10 (12.8%) 5.67 (1.95-16.49) .0008
Chronic GVHD 7 (26.9%) 9 (11.5%) 3.23 (0.97-10.73) .0571
GVHD of the skin (acute or chronic) 17 (65.4%) 12 (15.4%) 12.55 (3.59-43.78) < .0001
Corticosteroids, n (%) 5 (19.2%) 2 (2.6%) 13.14 (1.51-114.10) .0050
Liver dysfunction, n (%)
ALT >111.0 13 (50.0%) 20 (25.6%) 2.96 (1.13-7.77) .0236
AST >111.0 10 (38.5%) 8 (10.3%) 5.00 (1.68-14.88) .0028
Bilirubin >3.0 6 (23.1%) 5 (6.4%) 4.89 (1.19-20.04) .0224
Kidney dysfunction, n (%)
Creatinine > 2.0 6 (23.1%) 9 (11.5%) 2.08 (0.71-6.06) .1909
Neutropenia 2 (7.7%) 5 (6.4%) 1.22 (0.216-6.94) .8208
Immune function, median (range)
CD4+ T cells/mL3 150 (0-1068) 193 (0-992) 1.00 (0.99-1.00) .9418
CD8+ T cells/mL3 122 (0-1570) 144 (0-1511) 1.00 (0.99-1.00) .9497
Serum IgG (mg/mL) 606 (123-1420) 813 (192-1915) 0.998 (0.99-1.00) .0460
Hospital length of stay, days, median (range) 27.5 (0.0-90.0) 2.5 (0-93) 1.042 (1.01-1.06) < .0001
1432 Biol Blood Marrow Transplant 14:1429-1433, 2008C. N. Mihu et al.substantial morbidity due to focal infections and per-
sistent bacteremia requiring prolonged hospitalization
and treatment.
We next conducted a nested case-controlled study
to identify predictors for late SAB bacteremia and to
help develop guidelines for managing patients at high
risk for SAB. Nested case-controlled studies offer sev-
eral advantages over traditional case-controlled stud-
ies; they eliminate recall bias and can establish
a temporal relationship between putative risk factors
and outcomes [11]. The limitations of our study are in-
herent to its retrospective nature and limited sample
size. We cannot exclude a potential selection bias, be-
cause nondiseased persons from whom the controls
were selected may not be fully representative of the
original cohort. There was no routine surveillance dur-
ing our study period; thus, previous colonization with
S aureus is unknown. Our study is the largest study of
postengraftment SAB in allogeneic HSCT reported
to date. We have identified important risk factors and
provided practical guidance in antibiotic selection.
aGVHD involving any organ were associated with
late SAB. In particular, skin involvement by GVHD
was found to be a major risk factor for late SAB. Integ-
rity of the skin and mucus membranes constitutes the
first line of defense against invading pathogens. The
immune suppression and multiple comorbidities re-
lated to GVHD and its treatment likely contributed
to the high rates of persistent late SAB (54.5% of cases
surviving . 7 days from the first positive culture).
Corticosteroids are known to increase the suscepti-
bility to infection. More specifically, corticosteroidsTable 3. Multivariate Model of Factors Associated with Late SAB
Variable Cases (n 5 26) Con
Hospital LOS, days, median (range) 28 (0-90) 2
Skin GVHD, n (%) 17 (65.4%)
*Wald statistic; the P value for the likelihood ratio test for the entire model isare a major risk factor for invasive fungal infections in
HSCT. We found a specific association between corti-
costeroiduseandSAB. Inconcurrencewithourfindings,
inapreviouslyreportedMRSAoutbreakina transplanta-
tion unit, allogeneic HSCT recipients who developed
MRSA bacteremia were more likely to have GVHD,
and MRSA was definitely or possibly implicated in half
of the deaths occurring in these patients [12].
Liver and kidney dysfunction were associated with
SAB, but failed to show a statistically significant associ-
ation with late SAB in the multivariate analysis, sug-
gesting multicollinearity between these risk factors.
Markers of immune reconstitution of B cells andT cells
were not associated with SAB. Interestingly, prolonged
hospital LOS, likely representing a crude marker of
comorbidities and posttransplantation complications,
remained significant in multivariate analysis.
More than half of our patients had persistent SAB
bacteremia without evidence of focal infection. Most
of the cases of SAB were community-acquired. Al-
though patients undergoing HSCT are instructed to
seek prompt medical attention for infections, the lack
of fever in several of our patientsmay have led to a delay
in initiating treatment. Although the majority of pa-
tients had an indwelling CVC at the time of diagnosis,
in our experience the CVCwas not the initial source of
SAB in most of these cases. CVC removal was required
in most cases, however, due to either shock at pre-
sentation or persistent bacteremia, possibly due to
secondary CVC infection. Even after removal of
infected CVCs, most of our patients received pro-
longed (4 to 6 weeks) treatment because of persistenttrols (n 5 78)
Odds Ratio
(95% Confidence Interval) P Value*
.5 (0-93) 1.03 (1.00-1.06) .02
12 (15.4%) 8.87 (2.3-34.3) .002
<.0001.
Biol Blood Marrow Transplant 14:1429-1433, 2008 1433Late Staphylococcus aureus Bacteremia in BMTbacteremia and concern for possible secondary seeding
to major organs.
Although relatively rare in our cohort, S aureus was
themost common pathogen of bloodstream infection in
patients with skin GVHD during the study period. The
rate of MRSA isolates obtained from our patients was
lower than our institution’sMRSA rate during the study
period. Interestingly, the case fatality of MRSA bacter-
emia was higher than that of methicillin-susceptible
S aureus bacteremia (33% vs 10%). A larger study is
needed to investigate whether MRSA carries a higher
mortality inHSCTcomparedwithmethicillin-sensitive
isolates.
In summary, late SAB occurred mainly in patients
with GVHD or those receiving corticosteroid therapy.
In our immunosuppressed patients, shock, focal infec-
tions, and persistent bacteremia were common com-
plications. Clinical presentation of SAB was highly
variable; thus, we advocate a high index of suspicion
in high-risk patients. We recommend initiating of em-
piric antistaphylococcal therapy in these high-risk pa-
tients pending culture results. Although most of our S
aureus cases were community-acquired, vancomycin
should be considered in the initial treatment regimen,
because these patients are in close contact with the
health care environment, and MRSA isolates are in-
creasing in the community. Each institution should
tailor the empiric antibiotic regimen for patients at
high risk for late SAB based on rates of MRSA in
both the institution and the community.ACKNOWLEDGMENTS
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